Skip to main content

Remote Job Finders (RJF)

The Gap Between the Administration’s Pro-Innovation Words and Policy

Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.

AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B

The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.

Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership

The Global Fund to Fight AIDS, Tuberculosis and Malaria will work with Gilead and other private backers to ensure the HIV preventive Yeztugo, approved last month by the FDA, is available in low- and middle-income countries, concurrent with high-income nations.

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.

Six Startups Changing The Way We Age

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.
Scroll to top